TMEM161A

Across TCGA pan-cancer cohorts, TMEM161A Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TMEM161A data layer compared with 25 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TMEM161A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM161A expression acts as an unfavorable survival marker.

LUAD, LIHC, and LGG are the cancer types where TMEM161A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.167	0.814	<.001	48	view →
LIHC	DFS	Median	All	0.148	0.557	.004	9	view →
LGG	OS	Median	All	0.208	0.889	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TMEM161A–LUAD (OS)

Open the LUAD breakdown →